x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:00:00

TRANSFORM Trial: Overview and Potential Implications

CME/CE ·

2024/06/14

Guest: Pam R. Taub, MD, FACC, FASPC Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Guest: David J. Maron, MD Explore the future of cholesterol management with cutting-edge pharmacologic therapies and the latest research on lipid-lowering treatments. Understand the transformative impact of AI in primary cardiovascular disease prevention, as highlighted by groundbreaking trials like TRANSFORM. Stay informed on how emerging therapies can help patients achieve optimal

en

00:00:00

MACE and SGLT2 Inhibitors: Do They Have an Impact?

CME/CE ·

2024/06/14

Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Explore the future of cholesterol management with cutting-edge pharmacologic therapies and the latest research on lipid-lowering treatments. Understand the transformative impact of AI in primary cardiovascular disease prevention, as highlighted by groundbreaking trials like TRANSFORM. Stay informed on how emerging therapies can help patients achieve optimal LDL-C levels and reduce cardiovascular risks.

en

00:00:00

APPlexus Hot Topics 2024: Clinical Updates on...

CME/CE ·

2024/06/03

Host: Sandra E. Kurtin, PhD, ANP-BC, FAPO Guest: Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO On-demand webcast of expert faculty presentation and case discussion on treating patients with CLL and MCL with non-covalent BTK inhibitors, as presented at CCO and PCE’s APPlexus Hot Topics 2024.

en

00:00:00

Evolving Our View of the Coagulation Cascade and...

CME/CE ·

2024/05/30

Host: Valeria Caso, MD, PhD Guest: Ashkan Shoamanesh, MD How can you improve long-term secondary stroke prevention in patients with a history of noncardioembolic ischemic stroke or transient ischemic attack (TIA)? An understanding of how to apply emerging clinical trial data is critical, as is the evaluation of potential alternative agents that could expand the therapeutic options for these patients. In this activity, our expert faculty will add to your knowledge by reviewing the

en

00:00:00

Consolidation Immunotherapy After Concurrent CRT:...

CME/CE ·

2024/05/15

Host: Jhanelle E. Gray, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

en

00:00:00

Optimizing Consolidative Immunotherapy in...

CME/CE ·

2024/05/15

Host: Joshua E. Reuss, MD Guest: Jhanelle E. Gray, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

en

00:00:00

Immunotherapy Approaches in Unresectable Stage III...

CME/CE ·

2024/05/15

Host: Jhanelle E. Gray, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

en

00:00:00

Accurate Staging and Determining Resectability in NSCLC

CME/CE ·

2024/05/15

Host: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

en

00:00:00

Chemoradiotherapy Toxicities: How Do They Impact...

CME/CE ·

2024/05/15

Host: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

en

00:00:00

Consolidative Immunotherapy Following sCRT vs RT Only...

CME/CE ·

2024/05/15

Host: Jhanelle E. Gray, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

en

00:00:00

Consolidative Immunotherapy in Unresectable Stage III...

CME/CE ·

2024/05/15

Host: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

en

00:00:00

Differentiating and Managing Pneumonitis in...

CME/CE ·

2024/05/15

Host: Jhanelle E. Gray, MD Guest: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

en

00:00:00

Resolving Practice Barriers to Consolidative...

CME/CE ·

2024/05/15

Host: Jhanelle E. Gray, MD Guest: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

en

00:00:00

Selection of BTK Inhibitor Following Frontline...

CME/CE ·

2024/05/14

Host: Mazyar Shadman, MD, MPH Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer

en

00:00:00

Safety and Tolerability of Changing Covalent BTK...

CME/CE ·

2024/05/14

Host: Mazyar Shadman, MD, MPH Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer

en

00:00:00

Initial BTK Inhibitor-Based Treatment Selection in a...

CME/CE ·

2024/05/14

Host: Mazyar Shadman, MD, MPH Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer

en

00:00:00

Optimizing First-Line Immunotherapy for Recurrent or...

CME/CE ·

2024/05/03

Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

en

00:00:00

Overcoming Barriers to Equitable Care in HNSCC

CME/CE ·

2024/05/03

Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

en

00:00:00

Experts on the Ground: Data Updates on Emerging...

CME/CE ·

2024/04/25

Host: Richard Lafayette, MD, FACP Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.

en

00:00:00

Multidisciplinary Approach to Diagnosing and Managing...

CME/CE ·

2024/04/24

Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD Guest: Matthew J. Hamilton, MD Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-mediator intervention is not always successful in improving the quality of life of these patients. But the treatment landscape is changing. Join Drs. Cem Akin, Daniel DeAngelo, and Matthew Hamilton offer key clinical insights into this changing standard of

en

286 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事